-

Stephanie Reisinger to Lead Flatiron Health’s Real-World Evidence Business

Former Veradigm Executive Brings Extensive Experience in EHR-Derived Real-World Data

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced the appointment of Stephanie Reisinger as Senior Vice President and General Manager, Real-World Evidence (RWE), driving long-term strategy and growth for Flatiron’s RWE business unit.

“Stephanie brings a unique mix of expertise across electronic health records, real-world evidence, and analytics – the pillars of Flatiron’s work to learn from the experiences of every cancer patient,” said Carolyn Starrett, Flatiron CEO. “I’ve been deeply impressed by her perspective, accomplishments, and vision. Her leadership will help take our well-established products and evidence platform to the next level.”

Flatiron has led the field in the creation and use of RWE for oncology research and development (R&D). Today - together with a highly engaged care network of community sites, academic medical centers and health systems along with its life sciences and regulatory partners - Flatiron continues to drive and shape the future of oncology evidence generation.

Flatiron recognizes that to meaningfully accelerate R&D and access, to make research more inclusive and healthcare more sustainable, fundamental changes must be made in the way required data is collected, combined and analyzed. Through integrated evidence, knowledge can be generated in ways that go beyond today's methods – increasingly incorporating additional data modalities like genomics, claims and imaging; extending the stories told by clinical trial data with real-world data (RWD). Supported by Reisinger’s leadership, Flatiron will accelerate this vision to enable integrated evidence to power smarter care for every patient.

Prior to Flatiron, Reisinger served as the General Manager of Life Sciences Data and Analytics at Veradigm, an analytics subsidiary of Allscripts. She scaled the Life Sciences and RWE businesses, bridging the gap between Allscripts’ payer and provider data and life sciences partners, and oversaw operations and go-to-market strategy for this business unit. She has also held senior leadership positions in a variety of healthcare data and analytics organizations, including Evalytica, Evidera, United BioSource Corporation, ProSanos and GeneFormatics. Reisinger earned her bachelor’s degree at Widener University and is a candidate for her master’s in business administration at the Smeal College of Business at Penn State University.

“I am honored to join Flatiron, a global leader in transforming patients’ real-life experiences into knowledge to help accelerate improvements in cancer care and treatments,” said Reisinger. “I look forward to working closely with the organization's talented and mission-driven colleagues, as we continue to grow, lead and innovate. Flatiron has been at the forefront of developing real-world data for cancer research and I am delighted at the opportunity to be able to contribute to their mission and lead this next chapter of innovation alongside our partners.”

About Flatiron Health
Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Cancer is smart. Together, we can be smarter. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth

Contacts

Flatiron Health

Details
Headquarters: New York, NY
CEO: Carolyn Starrett
Employees: 2,500
Organization: PRI

Release Summary
Flatiron Health Appointment
Release Versions

Contacts

More News From Flatiron Health

Flatiron Health announces research to be presented at the 2025 San Antonio Breast Cancer Symposium

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at the San Antonio Breast Cancer Symposium (SABCS) happening from December 9-12, 2025, in San Antonio, Texas. Flatiron's real-world data and research capabilities are featured across multiple acceptances, including three spotlight presentations and four poster presentations that leverage the breadth of Flatiron’s breast cancer solutions. "Breast cancer is the most common cancer in women worldwide, and every patient's journe...

Flatiron Health announces research to be presented at the 2025 European Society For Medical Oncology AI & Digital Oncology Congress

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at the European Society For Medical Oncology AI & Digital Oncology Congress 2025 (ESMO AI) taking place on November 12-14 in Berlin, Germany. Flatiron’s experts will be presenting five pieces of research, in addition to leading the speaking session, “The VALID Framework for LLM-Extracted Oncology Data Quality: Comprehensive methodology for evaluating LLM-extracted real-world oncology data quality.” “Our research present...

Flatiron Health Announces Research to Be Presented at the 2025 American Society of Hematology’s Annual Meeting & Exposition

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition happening from December 6-9, 2025, in Orlando, Florida. Flatiron's real-world data and research capabilities are featured across multiple presentations, including 12 research acceptances spanning hematologic malignancies—from CAR T cell therapy delivery and outcomes to measurable residual disease (MRD) testing patterns and treatment equity across...
Back to Newsroom